InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,156.00
(
-0.27%
)
Dow Jones
39,150.33
(
0.00%
)
Brent Oil
84.71
(
0.82%
)
Bitcoin
61,318.11
(
-2.91%
)
Post# of 252313
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 123710

Wednesday, 08/03/2011 3:46:03 PM

Wednesday, August 03, 2011 3:46:03 PM

Post# of 252313
AMGN expects Teva to launch Neutroval (Neupogen FoB) in Nov 2013, but AMGN does not expect Teva to launch Neugranin (Neulasta FoB) in Nov 2013, according to AMGN’s 2Q11 CC. In other words, the settlement announced in #msg-65277106 ensures that Teva cannot launch Neugranin before Nov 2013, but it does not grant Teva a license to launch Neugranin in Nov 2013.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up